nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—IL1B—osteoporosis	0.533	1	CbGaD
Minocycline—SLC22A11—Conjugated Estrogens—osteoporosis	0.0794	0.296	CbGbCtD
Minocycline—SLC22A11—Estradiol—osteoporosis	0.0697	0.26	CbGbCtD
Minocycline—SLC22A8—Conjugated Estrogens—osteoporosis	0.0462	0.172	CbGbCtD
Minocycline—SLC22A8—Estradiol—osteoporosis	0.0405	0.151	CbGbCtD
Minocycline—SLC22A6—Conjugated Estrogens—osteoporosis	0.0322	0.12	CbGbCtD
Minocycline—IL1B—periosteum—osteoporosis	0.011	0.221	CbGeAlD
Minocycline—MMP9—periosteum—osteoporosis	0.00914	0.184	CbGeAlD
Minocycline—IL1B—vertebral column—osteoporosis	0.00908	0.183	CbGeAlD
Minocycline—CASP1—uterus—osteoporosis	0.00228	0.0459	CbGeAlD
Minocycline—CYCS—uterus—osteoporosis	0.00219	0.0442	CbGeAlD
Minocycline—CASP1—bone marrow—osteoporosis	0.00193	0.039	CbGeAlD
Minocycline—CASP3—uterus—osteoporosis	0.00188	0.0379	CbGeAlD
Minocycline—CYCS—bone marrow—osteoporosis	0.00186	0.0375	CbGeAlD
Minocycline—CASP3—bone marrow—osteoporosis	0.00159	0.0321	CbGeAlD
Minocycline—IL1B—uterus—osteoporosis	0.0015	0.0303	CbGeAlD
Minocycline—VEGFA—uterus—osteoporosis	0.00147	0.0298	CbGeAlD
Minocycline—IL1B—bone marrow—osteoporosis	0.00127	0.0257	CbGeAlD
Minocycline—VEGFA—bone marrow—osteoporosis	0.00125	0.0253	CbGeAlD
Minocycline—MMP9—uterus—osteoporosis	0.00125	0.0252	CbGeAlD
Minocycline—MMP9—bone marrow—osteoporosis	0.00106	0.0214	CbGeAlD
Minocycline—ALOX5—bone marrow—osteoporosis	0.000838	0.0169	CbGeAlD
Minocycline—CYCS—Fulvestrant—Estradiol—osteoporosis	0.000794	0.239	CbGdCrCtD
Minocycline—VEGFA—Estradiol—Estropipate—osteoporosis	0.000734	0.221	CbGdCrCtD
Minocycline—VEGFA—Estradiol—Conjugated Estrogens—osteoporosis	0.000556	0.167	CbGdCrCtD
Minocycline—CYCS—Levorphanol—Estradiol—osteoporosis	0.000525	0.158	CbGdCrCtD
Minocycline—VEGFA—Estradiol—Ethinyl Estradiol—osteoporosis	0.000467	0.141	CbGdCrCtD
Minocycline—CYCS—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000248	0.0748	CbGdCrCtD
Minocycline—VEGFA—Hemostasis—RAP1A—osteoporosis	6.2e-05	0.000424	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—IRS2—osteoporosis	6.19e-05	0.000424	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ACP5—osteoporosis	6.18e-05	0.000424	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—IL6R—osteoporosis	6.15e-05	0.000421	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—ANXA2—osteoporosis	6.14e-05	0.000421	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—SPP1—osteoporosis	6.14e-05	0.00042	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—TGFB1—osteoporosis	6.13e-05	0.00042	CbGpPWpGaD
Minocycline—CASP3—Integrated Breast Cancer Pathway—MYC—osteoporosis	6.08e-05	0.000416	CbGpPWpGaD
Minocycline—VEGFA—Platelet degranulation—TGFB1—osteoporosis	6.07e-05	0.000416	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IRS1—osteoporosis	6.03e-05	0.000413	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL6R—osteoporosis	6.02e-05	0.000412	CbGpPWpGaD
Minocycline—VEGFA—SHP2 signaling—IL6—osteoporosis	5.92e-05	0.000405	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ATIC—osteoporosis	5.91e-05	0.000405	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PNP—osteoporosis	5.91e-05	0.000405	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—WNT1—osteoporosis	5.89e-05	0.000403	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—IL6—osteoporosis	5.86e-05	0.000402	CbGpPWpGaD
Minocycline—IL1B—Immune System—ACTG1—osteoporosis	5.84e-05	0.0004	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	5.83e-05	0.000399	CbGpPWpGaD
Minocycline—CYCS—Transmembrane transport of small molecules—ADCY5—osteoporosis	5.83e-05	0.000399	CbGpPWpGaD
Minocycline—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoporosis	5.78e-05	0.000396	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—SOD2—osteoporosis	5.75e-05	0.000394	CbGpPWpGaD
Minocycline—CYCS—Metabolism—TPI1—osteoporosis	5.75e-05	0.000394	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—TNF—osteoporosis	5.73e-05	0.000392	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL6R—osteoporosis	5.66e-05	0.000388	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—IL6—osteoporosis	5.66e-05	0.000387	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—FGA—osteoporosis	5.62e-05	0.000385	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—MYC—osteoporosis	5.58e-05	0.000382	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—TGFB1—osteoporosis	5.56e-05	0.000381	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL6—osteoporosis	5.56e-05	0.000381	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TNF—osteoporosis	5.54e-05	0.00038	CbGpPWpGaD
Minocycline—IL1B—Senescence and Autophagy in Cancer—IL6—osteoporosis	5.53e-05	0.000379	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—TNF—osteoporosis	5.51e-05	0.000378	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—GPX1—osteoporosis	5.49e-05	0.000376	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—TNF—osteoporosis	5.47e-05	0.000375	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—IRS1—osteoporosis	5.41e-05	0.00037	CbGpPWpGaD
Minocycline—CYCS—Metabolism—P4HB—osteoporosis	5.41e-05	0.00037	CbGpPWpGaD
Minocycline—IL1B—Signaling by Interleukins—IL6—osteoporosis	5.4e-05	0.00037	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—IL6—osteoporosis	5.37e-05	0.000368	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MGLL—osteoporosis	5.37e-05	0.000367	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GAPDH—osteoporosis	5.31e-05	0.000363	CbGpPWpGaD
Minocycline—CASP1—Immune System—KL—osteoporosis	5.26e-05	0.000361	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—LRP5—osteoporosis	5.24e-05	0.000359	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—TNF—osteoporosis	5.2e-05	0.000356	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SOST—osteoporosis	5.18e-05	0.000355	CbGpPWpGaD
Minocycline—CYCS—Metabolism—RAP1A—osteoporosis	5.17e-05	0.000354	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—MYC—osteoporosis	5.14e-05	0.000352	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—ANXA2—osteoporosis	5.13e-05	0.000351	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TGFB1—osteoporosis	5.12e-05	0.000351	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—FGB—osteoporosis	5.11e-05	0.00035	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—IL6R—osteoporosis	5.08e-05	0.000348	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—IGF1—osteoporosis	5.07e-05	0.000347	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—MYC—osteoporosis	5.05e-05	0.000346	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	5.05e-05	0.000346	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TGFB1—osteoporosis	5.04e-05	0.000345	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—IL6—osteoporosis	5.03e-05	0.000345	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	5.03e-05	0.000345	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—OXCT1—osteoporosis	5.03e-05	0.000344	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CA2—osteoporosis	5.03e-05	0.000344	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	5.02e-05	0.000344	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—LRP6—osteoporosis	5.01e-05	0.000343	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—TNF—osteoporosis	4.99e-05	0.000342	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—MGLL—osteoporosis	4.9e-05	0.000336	CbGpPWpGaD
Minocycline—IL1B—Immune System—RAP1A—osteoporosis	4.88e-05	0.000334	CbGpPWpGaD
Minocycline—IL1B—Immune System—CTSK—osteoporosis	4.84e-05	0.000331	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TNF—osteoporosis	4.79e-05	0.000328	CbGpPWpGaD
Minocycline—IL1B—Immune System—NFATC1—osteoporosis	4.76e-05	0.000326	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TNF—osteoporosis	4.7e-05	0.000322	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	4.69e-05	0.000321	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CALCR—osteoporosis	4.69e-05	0.000321	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PTH1R—osteoporosis	4.69e-05	0.000321	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.62e-05	0.000316	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL1B—osteoporosis	4.58e-05	0.000314	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SOST—osteoporosis	4.5e-05	0.000308	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—IGF1—osteoporosis	4.49e-05	0.000308	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL6—osteoporosis	4.45e-05	0.000305	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	4.42e-05	0.000302	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TLN1—osteoporosis	4.23e-05	0.00029	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ENO1—osteoporosis	4.18e-05	0.000286	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—IDH2—osteoporosis	4.17e-05	0.000285	CbGpPWpGaD
Minocycline—CASP1—Immune System—AGER—osteoporosis	4.14e-05	0.000283	CbGpPWpGaD
Minocycline—CASP1—Immune System—ADCY5—osteoporosis	4.12e-05	0.000282	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PSMA2—osteoporosis	4.12e-05	0.000282	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PSMA5—osteoporosis	4.12e-05	0.000282	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CALCR—osteoporosis	4.07e-05	0.000279	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PTH1R—osteoporosis	4.07e-05	0.000279	CbGpPWpGaD
Minocycline—IL1B—Myometrial Relaxation and Contraction Pathways—IL6—osteoporosis	4.05e-05	0.000277	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL6—osteoporosis	4.04e-05	0.000276	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL6—osteoporosis	4.03e-05	0.000276	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CYP27A1—osteoporosis	3.92e-05	0.000268	CbGpPWpGaD
Minocycline—IL1B—Immune System—PSMA2—osteoporosis	3.89e-05	0.000266	CbGpPWpGaD
Minocycline—IL1B—Immune System—PSMA5—osteoporosis	3.89e-05	0.000266	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—TGFB1—osteoporosis	3.88e-05	0.000265	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—IL6R—osteoporosis	3.86e-05	0.000265	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL6—osteoporosis	3.86e-05	0.000264	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ACP5—osteoporosis	3.81e-05	0.000261	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.76e-05	0.000258	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—MGLL—osteoporosis	3.72e-05	0.000255	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—MYC—osteoporosis	3.66e-05	0.000251	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—P4HB—osteoporosis	3.65e-05	0.00025	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—LRP5—osteoporosis	3.64e-05	0.000249	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—IL6—osteoporosis	3.63e-05	0.000248	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—IL6—osteoporosis	3.62e-05	0.000248	CbGpPWpGaD
Minocycline—CASP1—Immune System—IRS2—osteoporosis	3.61e-05	0.000247	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PTH—osteoporosis	3.55e-05	0.000243	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—TPI1—osteoporosis	3.54e-05	0.000243	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—RAP1A—osteoporosis	3.49e-05	0.000239	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—LRP6—osteoporosis	3.48e-05	0.000238	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CNR2—osteoporosis	3.46e-05	0.000237	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—IL6—osteoporosis	3.42e-05	0.000234	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NFATC1—osteoporosis	3.4e-05	0.000233	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—DKK1—osteoporosis	3.37e-05	0.000231	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—IL6R—osteoporosis	3.35e-05	0.00023	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—IL6—osteoporosis	3.35e-05	0.000229	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CYP19A1—osteoporosis	3.34e-05	0.000229	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—P4HB—osteoporosis	3.33e-05	0.000228	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—TNF—osteoporosis	3.32e-05	0.000228	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—LEP—osteoporosis	3.29e-05	0.000225	CbGpPWpGaD
Minocycline—IL1B—Immune System—KL—osteoporosis	3.29e-05	0.000225	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GAPDH—osteoporosis	3.27e-05	0.000224	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—WNT1—osteoporosis	3.25e-05	0.000223	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MGLL—osteoporosis	3.23e-05	0.000221	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—RAP1A—osteoporosis	3.18e-05	0.000218	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—FGA—osteoporosis	3.16e-05	0.000217	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—LRP5—osteoporosis	3.16e-05	0.000216	CbGpPWpGaD
Minocycline—CASP1—Immune System—IRS1—osteoporosis	3.15e-05	0.000216	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	3.03e-05	0.000208	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	3.03e-05	0.000207	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.02e-05	0.000207	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—LRP6—osteoporosis	3.02e-05	0.000207	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL6R—osteoporosis	2.96e-05	0.000203	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PTHLH—osteoporosis	2.94e-05	0.000201	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—BMP2—osteoporosis	2.94e-05	0.000201	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TLN1—osteoporosis	2.94e-05	0.000201	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—FGB—osteoporosis	2.88e-05	0.000197	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—LEP—osteoporosis	2.86e-05	0.000196	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.83e-05	0.000194	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PSMA2—osteoporosis	2.78e-05	0.00019	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PSMA5—osteoporosis	2.78e-05	0.00019	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.78e-05	0.00019	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—IL6R—osteoporosis	2.76e-05	0.000189	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.74e-05	0.000188	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—IL6—osteoporosis	2.74e-05	0.000188	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ADCY5—osteoporosis	2.73e-05	0.000187	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GPX1—osteoporosis	2.72e-05	0.000186	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	2.69e-05	0.000184	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—TGFB1—osteoporosis	2.69e-05	0.000184	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL6—osteoporosis	2.68e-05	0.000184	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CALCA—osteoporosis	2.59e-05	0.000177	CbGpPWpGaD
Minocycline—IL1B—Immune System—AGER—osteoporosis	2.59e-05	0.000177	CbGpPWpGaD
Minocycline—IL1B—Immune System—ADCY5—osteoporosis	2.58e-05	0.000177	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ENO1—osteoporosis	2.57e-05	0.000176	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TLN1—osteoporosis	2.55e-05	0.000175	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PSMA2—osteoporosis	2.54e-05	0.000174	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PSMA5—osteoporosis	2.54e-05	0.000174	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—P4HB—osteoporosis	2.53e-05	0.000173	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL6—osteoporosis	2.52e-05	0.000173	CbGpPWpGaD
Minocycline—CYCS—Metabolism—MTHFR—osteoporosis	2.51e-05	0.000172	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PTH—osteoporosis	2.46e-05	0.000169	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RAP1A—osteoporosis	2.42e-05	0.000166	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CNR2—osteoporosis	2.4e-05	0.000164	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—IL6R—osteoporosis	2.39e-05	0.000164	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NFATC1—osteoporosis	2.36e-05	0.000162	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—KL—osteoporosis	2.35e-05	0.000161	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—DKK1—osteoporosis	2.34e-05	0.00016	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IGF1—osteoporosis	2.32e-05	0.000159	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.3e-05	0.000158	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—IL6—osteoporosis	2.26e-05	0.000155	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—WNT1—osteoporosis	2.26e-05	0.000155	CbGpPWpGaD
Minocycline—IL1B—Immune System—IRS2—osteoporosis	2.25e-05	0.000154	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL1B—osteoporosis	2.25e-05	0.000154	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—P4HB—osteoporosis	2.2e-05	0.000151	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—FGA—osteoporosis	2.2e-05	0.00015	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PTH—osteoporosis	2.14e-05	0.000146	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RAP1A—osteoporosis	2.1e-05	0.000144	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CNR2—osteoporosis	2.08e-05	0.000143	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CYP19A1—osteoporosis	2.06e-05	0.000141	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NFATC1—osteoporosis	2.05e-05	0.00014	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PTHLH—osteoporosis	2.04e-05	0.00014	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—BMP2—osteoporosis	2.04e-05	0.00014	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—DKK1—osteoporosis	2.03e-05	0.000139	CbGpPWpGaD
Minocycline—CYCS—Metabolism—POMC—osteoporosis	2.01e-05	0.000137	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—FGB—osteoporosis	2e-05	0.000137	CbGpPWpGaD
Minocycline—IL1B—Immune System—IRS1—osteoporosis	1.97e-05	0.000135	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—WNT1—osteoporosis	1.96e-05	0.000134	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PSMA2—osteoporosis	1.93e-05	0.000132	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PSMA5—osteoporosis	1.93e-05	0.000132	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.92e-05	0.000132	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—FGA—osteoporosis	1.91e-05	0.000131	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL6R—osteoporosis	1.85e-05	0.000127	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ADCY5—osteoporosis	1.84e-05	0.000126	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CALCA—osteoporosis	1.8e-05	0.000123	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SPP1—osteoporosis	1.78e-05	0.000122	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PTHLH—osteoporosis	1.77e-05	0.000121	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—BMP2—osteoporosis	1.77e-05	0.000121	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—IL6—osteoporosis	1.76e-05	0.000121	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—FGB—osteoporosis	1.73e-05	0.000119	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—IL6—osteoporosis	1.72e-05	0.000118	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ADCY5—osteoporosis	1.68e-05	0.000115	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GPX1—osteoporosis	1.68e-05	0.000115	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PSMA5—osteoporosis	1.67e-05	0.000115	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PSMA2—osteoporosis	1.67e-05	0.000115	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—KL—osteoporosis	1.63e-05	0.000112	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TGFB1—osteoporosis	1.63e-05	0.000112	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IRS2—osteoporosis	1.61e-05	0.00011	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—LEP—osteoporosis	1.58e-05	0.000108	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CALCA—osteoporosis	1.56e-05	0.000107	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—MTHFR—osteoporosis	1.55e-05	0.000106	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TNF—osteoporosis	1.52e-05	0.000104	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ESR1—osteoporosis	1.5e-05	0.000103	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—IL6—osteoporosis	1.49e-05	0.000102	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—KL—osteoporosis	1.42e-05	9.7e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TGFB1—osteoporosis	1.41e-05	9.69e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IRS1—osteoporosis	1.41e-05	9.63e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—TGFB1—osteoporosis	1.39e-05	9.51e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—POMC—osteoporosis	1.35e-05	9.27e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TNF—osteoporosis	1.32e-05	9.05e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL6R—osteoporosis	1.32e-05	9.05e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL6—osteoporosis	1.32e-05	9.03e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF1—osteoporosis	1.3e-05	8.92e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ADCY5—osteoporosis	1.28e-05	8.75e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—POMC—osteoporosis	1.24e-05	8.47e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SPP1—osteoporosis	1.24e-05	8.47e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—IL6—osteoporosis	1.23e-05	8.41e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IRS2—osteoporosis	1.12e-05	7.66e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ADCY5—osteoporosis	1.11e-05	7.6e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—LEP—osteoporosis	1.09e-05	7.49e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SPP1—osteoporosis	1.07e-05	7.35e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—IL6—osteoporosis	1.07e-05	7.3e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ESR1—osteoporosis	1.04e-05	7.15e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IRS1—osteoporosis	9.76e-06	6.69e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IRS2—osteoporosis	9.71e-06	6.65e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—LEP—osteoporosis	9.5e-06	6.51e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—POMC—osteoporosis	9.4e-06	6.44e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL6R—osteoporosis	9.17e-06	6.28e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ESR1—osteoporosis	9.07e-06	6.21e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF1—osteoporosis	9.04e-06	6.19e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IRS1—osteoporosis	8.47e-06	5.8e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL6—osteoporosis	8.24e-06	5.64e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—POMC—osteoporosis	8.16e-06	5.59e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL6R—osteoporosis	7.96e-06	5.45e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF1—osteoporosis	7.85e-06	5.38e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MYC—osteoporosis	7.83e-06	5.36e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TGFB1—osteoporosis	7.81e-06	5.35e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL6—osteoporosis	5.88e-06	4.03e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—MYC—osteoporosis	5.43e-06	3.72e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TGFB1—osteoporosis	5.42e-06	3.71e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MYC—osteoporosis	4.72e-06	3.23e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TGFB1—osteoporosis	4.71e-06	3.22e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL6—osteoporosis	4.08e-06	2.8e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL6—osteoporosis	3.55e-06	2.43e-05	CbGpPWpGaD
